Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137

Thomas C Wehler1, Michael Karg, Eva Distler

  • 1Department of Medicine III - Hematology and Oncology, Johannes Gutenberg-University of Mainz, Mainz, Germany.

Insights

A new method uses CD137 (4-1BB) expression to identify and isolate antigen-specific CD4(+) and CD8(+) T cells. This approach detects more virus-reactive T cells than current methods, aiding immunotherapy research.

Area of Science:

  • Immunology
  • Cell Biology
  • T-cell immunology

Background:

  • Current methods for T-cell isolation rely on peptide/MHC multimers or cytokine production.
  • These methods have limitations in detecting the full spectrum of antigen-specific T cells.

Purpose of the Study:

  • To investigate the de novo cell surface expression of CD137 (4-1BB) as a marker for activated human CD4(+) and CD8(+) memory T cells.
  • To establish a novel method for detecting and isolating antigen-specific T cells.

Main Methods:

  • Analysis of CD137 expression on human CD4(+) and CD8(+) T cells after antigen stimulation.
  • Co-staining with peptide/HLA tetramers to confirm specificity.
  • Comparison of CD137-based enrichment with IFN-gamma secretion assay for isolating virus-reactive T cells.
  • Magnetic-activated cell sorting (MACS) for purification and in vitro expansion of CD137(+) T cells.

Main Results:

  • CD137 is expressed on recently activated, but not resting, human CD4(+) and CD8(+) memory T cells.
  • Maximum CD137 expression occurs 24 hours post-antigen stimulation.
  • CD137(+) T cells represent a broader repertoire of antigen-specific T cells, including those not producing IFN-gamma.
  • CD137-based enrichment yielded 2-fold higher numbers of anti-viral T cells compared to the IFN-gamma assay.

Conclusions:

  • Antigen-triggered CD137 expression provides a rapid method for detecting and sorting virus-reactive CD4(+) and CD8(+) T cells.
  • The CD137 assay is valuable for monitoring anti-viral T helper and effector cells in immunotherapy and clinical trials.